By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Five Prime Therapeutics, Inc. 

2 Corporate Drive
Suite 200
San Francisco  California  94080  U.S.A.
Phone: 415-365-5600 Fax: 415-365-5601


Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics to alter the tumor microenvironment to enhance tumor cell killing. Our company has a growing portfolio of product candidates and currently has three protein therapeutics in clinical development.

• Cabiralizumab (FPA008) – a monoclonal antibody targeting CSF1R in a Phase 1/2 clinical trial in pigmented villonodular synovitis (PVNS) and in a Phase 1a/1b clinical trial in multiple cancers in combination with Bristol-Myers Squibb Company’s PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab)

• FPA144 – a monoclonal antibody targeting FGFR2b in a Phase 1 clinical trial in FGFR2b over-expressing gastric cancer

• FP-1039 – an FGF ligand trap in a Phase 1b clinical trial in mesothelioma

Five Prime has a differentiated target discovery platform and library that we use to rapidly interrogate the entire extracellular proteome in medically relevant in vitro and in vivo models to discover novel targets and drug leads. Our technology has been validated by our growing pipeline and through multiple collaborations with pharmaceutical companies, including Bristol-Myers Squibb, UCB Pharma, S.A. and GlaxoSmithKline across a range of therapeutic areas. FivePrime is committed to innovation and outstanding science, values that are reflected in our people and our products. Discover more about FivePrime at

Key Statistics

Ownership: Public

Web Site: Five Prime
Symbol: FPRX


Company News
Ablexis Announces Licensing Of The Alivamab Mouse To Five Prime (FPRX) 9/14/2017 8:14:56 AM
Five Prime (FPRX) Presents Preclinical Research Data On Novel B7-H4 Therapeutic Antibody At ESMO 2017 Congress 9/11/2017 11:47:51 AM
Five Prime (FPRX) Announces Updated Data In Mesothelioma Patients From Ongoing Phase Ib Trial Of FP-1039 At ESMO 2017 Congress 9/11/2017 11:46:46 AM
Five Prime (FPRX) Terminates $460 Million Immuno-oncology Deal With This SoCal Biotech 8/30/2017 7:19:32 AM
Five Prime (FPRX) Adds Former CytomX (CTMX)-Genentech (RHHBY) Immuno-Onco Vet To The Roster 8/18/2017 6:41:09 AM
Five Prime (FPRX) Announces Second Quarter 2017 Results And Provides Business Update 8/9/2017 1:33:42 PM
Five Prime (FPRX) To Announce Second Quarter 2017 Financial Results And Host Conference Call On August 8 7/27/2017 1:07:18 PM
Five Prime (FPRX)'s Founder And CEO To Step Down In 2018 6/22/2017 6:22:20 AM
Protagonist (PTGX) Appoints Five Prime (FPRX) CEO, Lewis T. "Rusty" Williams, To Its Board Of Directors 6/8/2017 8:06:01 AM
Five Prime (FPRX) Presents Initial Clinical Trial Data From Phase I/II Trial Of Cabiralizumab In Pigmented Villonodular Synovitis (PVNS) At 2017 ASCO Annual Meeting 6/5/2017 12:53:49 PM